Riskpilot← Back to searchSign inGet full accessVaering Läkarkonsult AB
ABActiveOrg 5569670770Vårgårdsvägen 31Medical specialists activities · NACE 8622Est. 20140 employees
Revenue 2025
SEK 1,3M
+12% vs 2024
EBITDA margin
98.4%
+71% vs 2024
Equity ratio
62.2%
Financial strength
Net profit 2025
SEK 752K
+76% vs 2024
| Revenue | SEK 1,3M | +12% |
| EBITDA | SEK 1,2M | +71% |
| Net profit | SEK 752K | +76% |
| Total assets | SEK 1,7M | +100% |
| Equity | SEK 1M | +107% |
| Employees | 0 | — |
Legal name
Vaering Läkarkonsult AB
Org number
5569670770
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
1 april 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Klinisk medicin, samt handel och förvaltning av värdepapper fast och lös egendom, och därmed förenlig verksamhet.
Address
Vårgårdsvägen 31
Email
t.arnljots@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 578 | 1 589 | 1 617 | 1 118 | 1 251 |
| Staff expenses | — | −906 | −930 | −244 | −18 |
| EBITDA | 967 | 564 | 582 | 721 | 1 232 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 967 | 564 | 582 | 721 | 1 232 |
| Net financials | — | 9 | −1 | −1 | 17 |
| Profit before tax | 967 | 572 | 581 | 540 | 949 |
| Tax | −198 | −118 | −120 | −112 | −197 |
| Net profit | 769 | 455 | 461 | 428 | 752 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 262 | 1 002 | 803 | 843 | 1 685 |
| Equity | 851 | 505 | 511 | 507 | 1 049 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 411 | 497 | 292 | 156 | 157 |
| Total debt | 411 | 497 | 292 | 156 | 157 |
EBITDA margin
98.4%
This company
15.8%
Market median
+523% vs market
20212025
Equity ratio
62.2%
This company
38.2%
Market median
+63% vs market
20212025
Return on equity
71.7%
This company
18.4%
Market median
+290% vs market
20212025
Net profit margin
60.1%
This company
8.1%
Market median
+642% vs market
20212025
Asset turnover
0.74×
This company
1.12×
Market median
-34% vs market
20212025
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TS Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Vaering Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thorsteinn Snaebjörnsson Arnljots | Chief Executive Officer | 0 companies |
| Urszula Arnljots | Deputy Board Member | 0 companies |
| Kanitta Arnljots | Deputy Board Member | 0 companies |